Advancements in lung cancer: molecular insights, innovative therapies, and future prospects

Abstract

Still among the most common and deadly cancers worldwide, lung cancer causes major morbidity and death. Thanks to late-stage diagnosis, tumor heterogeneity, and resistance to traditional treatments, the prognosis for lung cancer patients is still poor even with developments in medical research. The disease is driven by a sophisticated interaction of environmental elements, genetic alterations, and lifestyle choices like smoking, air pollution, and occupational toxins. Key driver mutations like KRAS, EGFR, ALK, and TP53-which affect tumor development and response to therapy-have been found by advances in molecular oncology. Imaging techniques (CT, MRI, PET-CT), molecular diagnostics, and biopsy-based procedures increasing early detection and categorization have fundamentally changed diagnostic methodologies. Depending on tumor stage and molecular profile, treatment modalities including surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy have varied degrees of success. Still major problems, though, include systematic toxicity and treatment resistance. By improving therapeutic targeting and reducing unwanted effects, emerging drug delivery methods such liposomal formulations, nanoparticle-based carriers, and inhalable medicines present interesting substitutes. Moreover, customized medicine is being opened by gene therapy and RNA-based therapeutics like siRNA treatments and CRISpen/Cas9 gene editing. Integration of artificial intelligence (AI), exosome-based drug carriers, and 3D bioprinting to improve therapeutic accuracy will be the main topics of future study. Emphasizing the importance of multidisciplinary approaches to increase survival rates and patient outcomes, this review investigates the etiology, molecular pathways, present therapy options, and developing discoveries in lung cancer research.

Keywords: Chemotherapy; Drug delivery; Liposome; Lung cancer; Targeted drug delivery system.